Gillott D J, Iles R K, Chard T
Academic Unit of Reproductive Physiology, Obstetrics and Gynaecology, St. Bartholomew's Hospital, West Smithfield, London, UK.
Br J Cancer. 1996 Feb;73(3):323-6. doi: 10.1038/bjc.1996.56.
The effects of human chorionic gonadotrophin (hCG) and its subunits on in vitro bladder cancer cell growth have been assessed using the a tetrazolium salt reduction assay (MTT). Intact hCG, alpha-hCG and beta-core hCG all had no effect on cell growth, while beta-hCG increased MTT reduction in all four bladder cancer lines tested. The magnitude of beta-hCG stimulation was maximal in the T24 line, which does not itself produce beta-hCG and appeared to be correspondingly lower in beta-hCG-secreting lines. The addition of antibodies to beta-hCG inhibited MTT reduction among high secretors but failed to inhibit MTT reduction in non-beta-hCG producers. These results are consistent with the poor prognosis associated with beta-hCG expression by bladder tumours in vivo and suggest an autocrine/paracrine stimulation of tumour growth by endogenously produced beta-hCG.
使用四氮唑盐还原法(MTT)评估了人绒毛膜促性腺激素(hCG)及其亚基对体外膀胱癌细胞生长的影响。完整的hCG、α-hCG和β-核心hCG对细胞生长均无影响,而β-hCG在所有测试的四种膀胱癌细胞系中均增加了MTT还原。β-hCG刺激的幅度在不自身产生β-hCG的T24细胞系中最大,而在分泌β-hCG的细胞系中相应较低。添加β-hCG抗体可抑制高分泌者的MTT还原,但未能抑制非β-hCG产生者的MTT还原。这些结果与体内膀胱肿瘤β-hCG表达相关的不良预后一致,并提示内源性产生的β-hCG对肿瘤生长有自分泌/旁分泌刺激作用。